Isoflucypram cardiovascular toxicity in zebrafish (Danio rerio)

Isoflucypram belongs to the new generation of succinate dehydrogenase inhibitor (SDHI) fungicides that are commonly used in crop fungal disease control. Evidence indicates that isoflucypram poses a potential risk to aquatic organisms. However, the effects of isoflucypram during early embryogenesis are not fully understood. In the present study, zebrafish embryos were exposed to 0.025, 0.25, or 2.5 mu M isoflucypram for three days. Isoflucypram caused severe developmental abnormalities (yolk sac edema, pericardial edema, and blood clotting clustering), hatching delay, and decreased heart rates in zebrafish. The expression levels of cardiac-specific genes (nkx2.5, myh7, myl7, and myh6) and erythropoiesis-related genes (gata1a, hbbe1, hbbe2, and alas2) were disrupted after isoflucypram exposure. Furthermore, enrichment analysis indicated that most of the differentially expressed genes (DEGs) were enriched in heart development or hemopoiesis processes. Overall, these findings suggest that exposure to isoflucypram is associated with developmental and cardiovascular toxicity in zebrafish. (c) 2021 Elsevier B.V. All rights reserved.

Automated summary

The study found that exposure to isoflucypram may cause developmental abnormalities, hatching delay, and decreased heart rates in zebrafish embryos, affecting the expression levels of cardiac-specific genes and erythropoiesis-related genes. Furthermore, most of the differentially expressed genes were enriched in heart development or hemopoiesis processes.